Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05582096 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3457263 in Obese Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT05582096 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 38 participants.
The verdict
NCT05582096, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the safety and tolerability of LY3457263 when administered in combination with tirzepatitide in overweight or obese participants. The study will also evaluate how much of LY3457263 gets into the blood stream and how long it takes the body to remove it in overweight or obese participants. The study will last up to approximately 11 weeks.
Interventions
- DRUG Placebo
- DRUG Tirzepatide
- DRUG LY3457263
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2022-11-11 |
| Est. Completion | 2023-06-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05582096
The ClinicalTrials.gov registry entry for NCT05582096 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 38 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05582096 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05582096 about?
NCT05582096 is a clinical study titled "A Study of LY3457263 in Obese Participants". The main purpose of this study is to evaluate the safety and tolerability of LY3457263 when administered in combination with tirzepatitide in overweight or obese participants. The study will also evaluate how much of LY3457263 gets into the blood stream and how long it takes the body to remove it in...
What is the current status of trial NCT05582096?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2022-11-11. Estimated completion is 2023-06-08.
What interventions are being tested in trial NCT05582096?
The interventions under investigation include: Placebo (DRUG), Tirzepatide (DRUG), LY3457263 (DRUG).
Who is sponsoring clinical trial NCT05582096?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.